Skip to main content
D&D Pharmatech Inc. logo

D&D Pharmatech Inc. — Investor Relations & Filings

Ticker · 347850 ISIN · KR7347850000 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2025-06-16 Regulatory Filings
Country KR South Korea
Listing KO 347850

About D&D Pharmatech Inc.

http://www.ddpharmatech.com/

D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 Topline data 수령)
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure filed by D&D Pharmatech regarding the 'Topline data' results of a Phase 2 clinical trial for their MASH treatment, DD01. It follows the standard format for Korean Stock Exchange (KRX) disclosures concerning 'Major Management Matters' (Investment Judgment). Since it reports specific clinical trial outcomes and regulatory progress rather than a general financial report or a simple announcement of a report's availability, it falls under the category of general regulatory filings for material corporate events.
2025-06-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This is a standard regulatory filing used to disclose insider trading or changes in share ownership by company directors or major shareholders. In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS).
2025-06-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose changes in their shareholdings. This corresponds to the 'Director's Dealing' (DIRS) category, which covers insider trades and ownership changes by company directors and executives.
2025-06-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used to disclose insider transactions, specifically the exercise of stock options by an executive (SungMook Lim). This falls under the category of Director's Dealing (DIRS).
2025-06-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and changes in holdings for a specific individual (Park Eun-ji, an executive at D&D Pharmatech). This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2025-06-13 Korean
주요사항보고서(자본으로인정되는채무증권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange. It details the decision to issue 'subordinated perpetual convertible bonds' (자본으로 인정되는 채무증권 발행결정). This is a formal regulatory filing regarding capital structure changes and financing activities. It is not an announcement of a report (RPA) but the primary disclosure of the financial transaction itself. Therefore, it fits best under 'Capital/Financing Update'.
2025-06-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.